Robert Harrison, MD
Cardiovascular Disease · Durham, NCNPI 1457547853
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $750 of the $750 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, ZOLL Services LLC (a/k/a ZOLL Lifecor Corp). That places this record below the midpoint for cardiovascular disease clinicians in NC, where the typical reported total is $1,959.
Across 1 payment — averaging $750.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$750
Across 10 payments — averaging $18,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$151K
- E.r. Squibb & Sons, L.L.C.$19K
- Datascope Corp.$15K
- Bayer$5K
What the payments were for
- Speaking & faculty fees$750100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $750 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$750
How this compares
$750 in reported general payments places this provider in the 30th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $101,394 |
| EntrestoSacubitril/Valsartan | 55 | $43,853 |
| Repatha SureclickEvolocumab | 46 | $37,169 |
| MultaqDronedarone Hcl | 16 | $28,520 |
| XareltoRivaroxaban | 19 | $20,620 |
| JardianceEmpagliflozin | 31 | $20,618 |
| Metoprolol Succinate | 117 | $2,156 |
| Rosuvastatin Calcium | 125 | $1,945 |
| Ezetimibe | 85 | $1,391 |
| Candesartan Cilexetil | 11 | $1,036 |
| Pravastatin Sodium | 26 | $785 |
| Carvedilol | 74 | $754 |
| Atorvastatin Calcium | 88 | $721 |
| Losartan Potassium | 64 | $647 |
| Amlodipine Besylate | 84 | $604 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.